| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 659.80 | 9.7% | 10.6% |
| Total Income | 684.20 | 9.4% | 10.0% |
| Expenditure | 529.80 | 4.0% | 9.6% |
| PBT | 124.30 | 39.0% | 10.1% |
| Net Profit | 91.40 | 40.0% | 6.8% |
| OPM | 22.61% | 8.06pp | 10.48pp |
| NPM | 13.36% | 6.79pp | 2.42pp |
| EPS | 5.42 | 70.0% | 53.3% |
Dr. Lal PathLabs Announces 10.6% Revenue Growth in Q3 FY26, PAT at Rs 91 Cr
30 Jan 2026 · 30 Jan, 1:45 pm
Summary
Dr. Lal PathLabs Limited, a leading diagnostic and related healthcare service provider, has announced its financial results for the quarter ended December 31, 2025. The company reported a 10.6% increase in revenue in Q3 FY26 and a 10.8% increase for the nine months ended Dec’25. The EBITDA before exceptional items for Q3 FY26 increased by 16.3% with a margin of 27.2%. The P&L for Q3 FY26 includes an exceptional impact of Rs 30.1 Cr on account of Labour codes. The PAT for Q3 FY26 is Rs 91 Cr. with a margin of 13.9%.
Key Highlights
- 1
Revenue increased by 10.6% in Q3 FY26 and by 10.8% for nine months ended Dec’25
- 2
EBITDA (before exceptional items) for Q3 FY26 increased by 16.3% with a margin of 27.2%
- 3
P&L for Q3 FY26 includes an exceptional impact of Rs 30.1 Cr on account of Labour codes
- 4
PAT for Q3 FY26 is Rs 91 Cr. with a margin of 13.9%
- 5
Cash and Bank balances as on 31‘ Dec, 2025 is Rs. 1,411 Cr.
Management Comments
Dr. Lal PathLabs Limited
Please find enclosed herewith the Press Release on the Un-audited Financial Results (Consolidated and Standalone) for the Quarter & Nine Months ended December 31, 2025. We request you to please take the same on record.
Informational and educational content only. Not investment advice.